Search research articles
Contact Us
Filters
Showing results (11-20 of 18) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 18 results.
Archives of Neurology
|
August 26, 1998
Randomized, placebo-controlled study of tolcapone in patients with fluctuating Parkinson disease treated with levodopa-carbidopa. Tolcapone Fluctuator Study Group III
C H Adler, C Singer, C O'Brien, et al.
Neurology
|
October 26, 1999
Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia
M F Brin, M F Lew, C H Adler, et al.
Neurology
|
October 26, 1999
Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia
A Brashear, M F Lew, D D Dykstra, et al.
Neurology
|
September 26, 1997
Botulinum toxin type B: a double-blind, placebo-controlled, safety and efficacy study in cervical dystonia
M F Lew, B T Adornato, D D Duane, et al.
Neurology
|
September 26, 2001
Genome-wide scan for Parkinson's disease: the GenePD Study
A L DeStefano, L I Golbe, M H Mark, et al.
Neurology
|
December 28, 2006
Herbicide exposure modifies GSTP1 haplotype association to Parkinson onset age: the GenePD Study
J B Wilk, J E Tobin, O Suchowersky, et al.
Neurology
|
May 30, 2008
Haplotypes and gene expression implicate the MAPT region for Parkinson disease: the GenePD Study
J E Tobin, J C Latourelle, M F Lew, et al.
Neurology
|
February 27, 2001
A randomized, controlled trial of remacemide for motor fluctuations in Parkinson's disease
I Shoulson, J Penney, M McDermott, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 18) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 18 results.
Archives of Neurology
|
August 26, 1998
Randomized, placebo-controlled study of tolcapone in patients with fluctuating Parkinson disease treated with levodopa-carbidopa. Tolcapone Fluctuator Study Group III
C H Adler, C Singer, C O'Brien, et al.
Neurology
|
October 26, 1999
Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia
M F Brin, M F Lew, C H Adler, et al.
Neurology
|
October 26, 1999
Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia
A Brashear, M F Lew, D D Dykstra, et al.
Neurology
|
September 26, 1997
Botulinum toxin type B: a double-blind, placebo-controlled, safety and efficacy study in cervical dystonia
M F Lew, B T Adornato, D D Duane, et al.
Neurology
|
September 26, 2001
Genome-wide scan for Parkinson's disease: the GenePD Study
A L DeStefano, L I Golbe, M H Mark, et al.
Neurology
|
December 28, 2006
Herbicide exposure modifies GSTP1 haplotype association to Parkinson onset age: the GenePD Study
J B Wilk, J E Tobin, O Suchowersky, et al.
Neurology
|
May 30, 2008
Haplotypes and gene expression implicate the MAPT region for Parkinson disease: the GenePD Study
J E Tobin, J C Latourelle, M F Lew, et al.
Neurology
|
February 27, 2001
A randomized, controlled trial of remacemide for motor fluctuations in Parkinson's disease
I Shoulson, J Penney, M McDermott, et al.
Page
of 2